颅内出血患者抗凝与抗血小板药物不当使用:一级创伤中心的回顾性研究
该回顾性研究分析了2020至2022年一家三级创伤医院2662例颅内出血诊断,其中424例(15.9%)符合纳入标准。结果显示129例(30.4%)的抗凝或抗血小板使用不当,主要原因为适应证不符(58%)。研究提示神经外科医生应关注以阿司匹林81mg用于一级预防或双联抗血小板用于二级预防等无适应证的用药患者。
要点
- 颅内出血前抗凝/抗血小板使用不当比例达30.4%,主要因适应证不符。
- 常见不当用药包括阿司匹林81mg用于一级预防、双联抗血小板用于二级预防。
- 年龄、性别、种族、保险类型与用药不当无显著差异。
核心结论
- 超过30%的颅内出血患者在出血前使用抗凝或抗血小板药物不当,主要因适应证超出当前临床指南。
研究设计与样本
- 回顾性研究,纳入2020至2022年一家三级创伤医院所有颅内出血诊断,共2662例,其中424例(15.9%)符合纳入标准,定义为诊断前7天内使用抗凝或抗血小板药物。
主要发现
- 424例中129例(30.4%)的抗凝或抗血小板使用不当,其中适应证不当占58%。
- 比较适当与不适当用药组,年龄、性别、种族、保险类型无显著差异。
关键数值与推荐
- 用药适当性依据所有相关临床指南判定。
- 不当使用的主要原因为适应证不符(58%)。
- 常见不当用药包括阿司匹林81mg用于一级预防或双联抗血小板治疗用于二级预防。
临床怎么用
- 神经外科医生应识别颅内出血患者中可能无适应证使用抗凝/抗血小板药物的情况,特别是阿司匹林81mg用于一级预防或双联抗血小板用于二级预防。
- 与其他专科协作减少该人群的不必要风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Intracranial hemorrhage (ICH) is a known risk factor associated with the use of oral anticoagulants (ACs) and antiplatelets (APs). Guidelines regarding the initiation and continuation of both ACs and APs are heterogeneous and complex. The management of these drugs in the setting of ICH is a frequent problem encountered by neurosurgeons today. The objective of this study was to determine the proportion of appropriate and inappropriate use of ACs or APs before ICH based on current guidelines. The secondary objective was to identify specific patient subpopulations that are at higher risk for unindicated AC or AP use before ICH. METHODS: All ICH diagnoses at a tertiary trauma hospital from 2020 to 2022 were retrospectively reviewed for premorbid AC/AP use, defined as any AC/AP use occurring within 7 days before diagnosis. Demographics, hemorrhage characteristics, length of stay, and mortality data were collected. To determine appropriateness of medication use, the authors referenced all relevant clinical guidelines. RESULTS: Of 2662 ICH diagnoses, 424 (15.9%) met inclusion criteria. AC or AP use was deemed inappropriate in 129 (30.4%) encounters, among which improper indication (58%) was the leading cause for inappropriate use. No significant differences based on age, sex, race, or insurance were found when comparing appropriate vs inappropriate AC/AP use. CONCLUSION: This study demonstrates that more than 30% of patients taking AC/APs before ICH were doing so inappropriately, mostly due to indications that fell outside current clinical guidelines. Neurosurgical providers should be aware of which ICH patients are most likely to be taking unindicated AC/APs-namely, aspirin 81 mg for primary prevention or dual antiplatelet therapy for secondary prevention-and collaborate with other providers to reduce unnecessary risk in this patient population.
引用
- Nichols CS, Lesha E, Konakalla P, et al. Inappropriate Use of Anticoagulants and Antiplatelets in Intracranial Hemorrhage Patients: A Retrospective Study From a Tertiary Referral Level 1 Trauma Center. Neurosurgery. 2026. PMID: 42017653. doi:10.1227/neu.0000000000004052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。